Rhumbline Advisers Buys 64,530 Shares of Haemonetics Co. (HAE)

Rhumbline Advisers grew its stake in shares of Haemonetics Co. (NYSE:HAE) by 67.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 159,598 shares of the medical instruments supplier’s stock after buying an additional 64,530 shares during the period. Rhumbline Advisers owned 0.31% of Haemonetics worth $15,968,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Cardinal Capital Management increased its position in Haemonetics by 2.1% during the fourth quarter. Cardinal Capital Management now owns 8,100 shares of the medical instruments supplier’s stock worth $810,000 after buying an additional 163 shares in the last quarter. Belpointe Asset Management LLC increased its position in Haemonetics by 1.9% during the third quarter. Belpointe Asset Management LLC now owns 10,041 shares of the medical instruments supplier’s stock worth $1,150,000 after buying an additional 192 shares in the last quarter. Retirement Systems of Alabama increased its position in Haemonetics by 0.3% during the fourth quarter. Retirement Systems of Alabama now owns 67,012 shares of the medical instruments supplier’s stock worth $6,705,000 after buying an additional 210 shares in the last quarter. Bank of Montreal Can increased its position in Haemonetics by 17.8% during the fourth quarter. Bank of Montreal Can now owns 2,052 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 310 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Haemonetics by 1.1% during the fourth quarter. Arizona State Retirement System now owns 37,096 shares of the medical instruments supplier’s stock worth $3,711,000 after buying an additional 392 shares in the last quarter. 97.54% of the stock is owned by institutional investors.

In other news, SVP Jacqueline Scanlan sold 1,027 shares of Haemonetics stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $104.22, for a total value of $107,033.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard J. Meelia sold 8,196 shares of Haemonetics stock in a transaction on Friday, December 14th. The shares were sold at an average price of $102.86, for a total value of $843,040.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,916 shares of company stock valued at $1,124,301. Company insiders own 1.04% of the company’s stock.

Several equities analysts have weighed in on HAE shares. Zacks Investment Research downgraded Haemonetics from a “hold” rating to a “sell” rating in a research report on Thursday, January 24th. Barrington Research raised their price target on Haemonetics to $112.00 and gave the stock a “positive” rating in a research report on Wednesday, February 6th. Finally, ValuEngine downgraded Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $119.75.

Shares of NYSE:HAE opened at $84.06 on Tuesday. The firm has a market capitalization of $4.25 billion, a PE ratio of 44.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.89. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51. Haemonetics Co. has a 52 week low of $68.14 and a 52 week high of $117.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.04. The business had revenue of $247.36 million during the quarter, compared to the consensus estimate of $250.12 million. Haemonetics had a return on equity of 17.05% and a net margin of 4.84%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. On average, research analysts anticipate that Haemonetics Co. will post 2.33 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/02/12/rhumbline-advisers-buys-64530-shares-of-haemonetics-co-hae.html.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: How to find the components of the quick ratio

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply